Is There a Role for Retreating Patients With Late Onset Myosynia?

I wonder if you could explore a little bit how the results of ReinaMax will inform our longitudinal management of myosynia right. What do you see as the overall effect on the treatment paradigm for instance do you think that there's a role for retreating patients with retuximab periodically and I know this is a bit of conjecture perhaps you're following the cohort longitudinally. And what do you see the future holding? We had mostly late onset patients so with early onset myosynian something one could contemplate this whether one should do let's say antecedent 20 and then do thymectomy or not.